Use of biomarkers in occupational safety and health

Toxicologic Biomarkers

Volumn , Issue , 2006, Pages 201-220

  Sargent, Edward V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84155169744     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. National Research Council. Biological markers in environmental health research. Environ Health Perspect 1987; 74:3-9.
2. Hu HR, Kim R, Fleischaker G, Aro A. Measuring bone lead as a biomarker of cumulative lead dose. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: Medical and Workplace Applications. Washington: Joseph Henry Press, 1998:71-86.
3. American Conference of Governmental Industrial Hygienists. Biological Exposure Indices, Cincinnati: ACGIH, 2001.
4. Lauwerys RR. Occupational toxicology. In: Amdur MO, Doull J, Klaassen CD, eds. Toxicology-The Basic Science of Poisons. 4th ed., New York: McGraw-Hill, 1983.
5. Mutti A. Biological monitoring in occupational and environmental toxicology. Toxicol Lett 1999; 108:77-89.
6. McCunney RJ. Use of biomarkers in occupational medicine. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: Medical and Workplace Applications. Washington: Joseph Henry Press, 1998:377-386.
7. Bingham E. Ethical issues of genetic testing for workers. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: Medical and Workplace Applications. Washington: Joseph Henry Press, 1998:415-422.
8. Schulte PA, Rothman N. Epidemiological validation of biomarkers of early biological effect and susceptibility. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: Medical and Workplace Applications. Washington: Joseph Henry Press, 1998:23-32.
9. Naumann BD, Weidemann PA. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum Ecol Risk Assess 1995; 5:590-613.
10. Naumann BD, Weideman PA, Dixit R, Grossman SJ, Shen CF, Sargent EV. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Hum Ecol Risk Assess 1997; 3:555-565.
11. Health and Safety Executive (UK) Laboratory Methods for Biological Monitoring. London: HMSO, 1985.
12. Deutsche Forschungsgemeinschaft (DFG). List of MAK and BAT values. Report No. 30; Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area. Weinheim: UCH Verlagsgesellschaft mbh, 1994.
13. Lauwerys RR. Industrial Chemical Exposure: Guidelines for biological monitoring. Davis: Biomedical Publications, 1983.
14. Hu HA, Aro A, Rotnitzky A. Bone lead measured by x-ray fluorescence: Epi-demiological methods and a new biomarker. Environ Health Perspect 1995; 103(suppl 1):105-110.
15. Watson WP, Mutti A. Role of biomarkers in monitoring exposures to chemicals: present position, future prospects. Biomarkers 2004; 9:211-242.
16. American Conference of Governmental Industrial Hygienists (ACGIH). The Documentation of the TLVs and BEIs with Other Worldwide Occupational Exposure Values. Cincinnati: ACGIH, 2004.
17. Organization for Economic Cooperation and Development (OECD). Decision of the Council Concerning the Mutual Acceptance of Data in the Assessment of Chemicals. Paris: OECD, 1981.
18. International Standards Organization (ISO). Guide 25; General Requirements for the Competence of Calibration and Testing Laboratories, 3rd ed., Geneva: ISO, 1989.
19. U.S. Food and Drug Administration (FDA). Good laboratory practice for non-clinical laboratory studies, Code of Federal Regulations 1986; 21:227-240.
20. Occupational Safety and Health Administration. Lead. 29 CFR Part 1910.1025, Washington: U.S. Department of Labor, Government Printing Office, 1999.
21. Schroeder HA, Tipton IH. The human body burden of lead. Arch Environ Health 1968; 17:965-978.
22. 109Cd sources: radiation dosimetry studies. Environ Res 1992; 57:117-132.
23. Weaver VM, Jaar BG, Schwartz BD, et al. Associations among lead dose biomarkers, uric acid and renal function in Korean lead workers. Environ Health Perspect 2005; 113:36-42.
24. Schwartz BS, Lee B, Lee G, et al. Association of blood lead, dimercaptosuccinic acid-chelatable lead and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol 2001; 153:453-464.
25. Collins AR. Molecular epidemiology in cancer research. Mol Aspects Med 1998; 19:359-432.
26. Hemminki K, Dipple A, Shuker DG, Kadluber F, Segerback D, Bautsch H. DNA Adducts: Identification and Biological Significance. In: IARC Publication No. 125. Lyon: International Agency for Research on Cancer, 1994.
27. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis 1993; 14: 1007-1012.
28. Hemminki K. DNA adducts in biomonitoring. J Occup Environ Med 1995; 37: 44-51.
29. Ehrenberg L, Osterman-Golkar S, Segerback D, Svensson K, Calleman CJ. Evaluation of genetic risks of alkylating agents III. Alkylation of hemoglobin after metabolic conversion of ethene to oxide in vivo. Mutat Res 1977; 45: 175-184.
30. Ehrenberg L, Osterman-Golkar S. Alkylation of macromolecules for detecting mutagenic agents. Teratogen Carcinogen Mutagen 1980; 1:105-127.
31. Boogaard PJ. Use of hemoglobin adducts in exposure monitoring and risk assessment. J Chromatogr B 2002; 778:309-322.
32. Calleman CJ, Ehrenberg L, Jansson B, et al. Monitoring and risk assessment by means of alkyl groups in hemoglobin in persons occupationally exposed to ethylene oxide. J Environ Pathol Toxicol 1987; 2:427-442.
33. Osterman-Golkar S, Bergmark E. Occupational exposure to ethylene oxide: relation between in vivo dose and exposure dose. Scand J Work Environ Health 1988; 14:372-377.
34. Van Sittert NJ, De Jong G, Clare MG, et al. Cytogenetic immunological and hematological effects in workers in an ethylene oxide manufacturing plant. Br J Ind Med 1985; 42:19-26.
35. Czene K, Osterman-Golkar S, Yun X, et al. Analysis of DNA and hemoglobin adducts and sister chromatid exchanges in a human population occupationally exposed to propylene oxide: a pilot study. Cancer Epidemiol Biomarkers Prev 2002; 11:315-318.
36. Skipper PL, Tannenbaum SR. Molecular dosimetry of aromatic amines in human populations. Environ Health Perspect 1994; 102(suppl 6):17-21.
37. Bergmark E, Calleman CJ, He F, Costa LG. Hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol Appl Pharmacol 1993; 120:45-54.
38. Bergmark E. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory personnel, smokers, and non smokers. Chem Res Toxicol 1997; 10:78-84.
39. Osterman-Golkar S, Peltonen K, Anttinen-Ylemetti T, Landin HH, Zorcec V, Sorsa M. Hemoglobin adducts as biomarkers of occupational exposure to 1,3-butadiene. Mutagenesis 1996; 11:145-149.
40. Yeowell-O'Connell K, Rothman N, Waidyanatha S, et al. Cancer Epidemiol Biomarkers Prev 2001; 10:831-838.
41. Farmer PB. Studies using specific biomarkers for human exposure assessment to exogenous and endogenous chemical agents. Mutat Res 1999; 428:69-81.
42. Tornqvist MJ, Mowrer J, Jensen S, Ehrenberg L. Monitoring of environmental cancer initiators through hemoglobin adducts by a modified Edman degradation method. Anal Biochem 1986; 154:255-266.
43. Boogaard PJ, Rocchi PSJ, VanSittert NJ. Biomonitoring of exposure to ethy-lene oxide and propylene oxide by determination of hemoglobin adducts: correlations between airborne exposure and adduct levels. Inter Arch Occup Environ Health 1999; 72:142-150.
44. Segerback D, Osterman-Golkar S, Molholt B, Nilsson R. In vivo tissue dosime-try as a basis for cross-species extrapolation in cancer risk assessment for pro-pylene oxide. Regul Toxicol Pharmacol 1994; 20:1-14.
45. Nilsson R, Molholt B, Sargent EV. Quantitative assessment of a human carcinogenic potency for propylene oxide. Regul Toxicol Pharmacol 1991; 14:229-244.
46. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 35: Polynuclear aromatic compounds, Lyon: IARC, 1985.
47. Jongeneelen FJ. Benchmark guideline for urinary 1-hydroxy pyrene as biomarker for occupational exposure to polycyclic aromatic hydrocarbons. Ann Occup Hygiene 2001; 1:3-13.
48. Vanrooij JG, Van Lieshout M, Rodelier-Bade E, Jongeneelen FJ. Effect of the reduction of skin contamination on the internal dose of creosote workers exposed to PAH. Scand J Work Environ Health 1993; 19:200-207.
49. Jongenellen FJ, Anzion RB, Leijdekkers M, Bos RP, Henderson PT. 1- Hydro-xypyrene in human urine after exposure to coal tar and coal tar derived product. Int Arch Occup Environ Health 1985; 57:47-55.
50. Grimmer G, Dettbaur G, Naujack KW, Jacob J. Relationship between inhaled PAH and urinary excretion of phenanthrene, pyrene and benzo[a]pyrene metabolites in coke plant workers. Polycyclic Arom Comp. 1994; 5:269-277.
51. Lafontaine M, Gendre C, Morele Y, Laffitte-Rigeaud G. Excretion of urinary 1-hydroxypyrene in relation to the penetration routes of polycyclic aromatic hydrocarbons. Polycyclic Arom Hydrocarbons 2002; 22:579-588.
52. McClean MD, Rindhart RD, Ngo L, et al. Urinary 1-hydroxypyrene and poly-cyclic aromatic hydrocarbon exposure among asphalt paving workers. Ann Occup Hygiene 2004; 48:565-578.
53. Ny ET, Heederik D, Kromhout H, Jongeneelen F. The relationship between polycyclic aromatic hydrocarbons in air and in urine of workers in a Soderberg pot room. Am Ind Hygiene Assoc J 1993; 54:277-284.
54. Kuljukka TR, Vaaramrinta R, Veidebaum T, Sorsa M, Deltonen K. Exposure to PAH compound among cokery workers in the oil shale industry. Environ Health Perspect 1996; 104(suppl 3):539-554.
55. Lee KH, Ichiba M, Zhang JS, et al. Multiple biomarkers study in painters in a shipyard in Korea. Mutat Res 2003; 540:89-98.
56. Kang D, Rothman N, Cho SH, et al. Association of exposure to polycyclic aromatic hydrocarbons (estimated from job category) with concentration of 1-hydroxypyrene glucuronide in urine. Occup Environ Med 1995; 52:593-599.
57. Lauwery RR. Occupational toxicology. In: Cassarett M, Doull J, eds. Toxicology-The Basic Science of Poisons. New York: Pergamon Press, 1997:947-969.
58. Strickland PT, Routledge MN, Dipple A. Methodologies for measuring ofcarci-nogenic adducts in humans. Cancer Epidemiol Biomarkers Prev 1993; 2:607-619.
59. Brandt HCA, Watson WP. Monitoring human occupational and environmental exposures to polycyclic aromatic compounds. Ann Occup Hygiene 2003; 47:349-378.
60. MacGregor JT, Claxton LD, Lewtas J, Jensen R, Lower WR, Pesch GG. Monitoring environmental genotoxicants. In: Brusick DJ, ed. Methods for Genetic Risk Assessment, Boca-Raton: Lewis Publishers, 1994.
61. DeJong G, VanSittert NJ, Natarajan AT. Cytogenetic monitoring of industrial populations potentially exposed to genotoxic chemicals and of control populations. Mutat Res 1988; 204:451-464.
62. Hagmar L, Bellander T, Hogstedt B, et al. Biological effects in a chemical factory with mutagenic exposure. I. Cytogenetic and haematological parameters. Int Arch Occup Environ Health 1988; 60:437-444.
63. Nordic Study Group on the Health Risk of Chromosome Damage. A Nordic data base on somatic chromosome damage in humans. Mutat Res 1990; 241:325-337.
64. Hagmar L, Bonassi S, Stromberg U, et al. Cancer predictive value of cytoge-netic markers used in occupational health surveillance programs: a report from an ongoing study by the European Study Group on Cytogenetic Biomarkers and Health. Mutat Res 1998; 405:171-178.
65. Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Gen Cytogen 1995; 79:133-135.
66. Hagmar LA, Brogger IL, Hansteen S, et al. Cancer risk in humans predicted by increased levels ofchromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994; 54:2919-2922.
67. Bonassi S, Hagmar L, Stromberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens- European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 2000; 60:1619-1625.
68. Hagmar L, Stromberg U, Bonassi S, et al. Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts. Cancer Res 2004; 64:2258-2263.
69. Hagmar L, Brogger A, Hansteen IL, et al. Cancer risk in humans predicted by increased levels ofchromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994; 54:2919-2922.
70. Albertini RJ, Robison SH. Human population monitoring. In: Li AP, Heflich RH, eds. Genetic Toxicology. Boca Raton: CRC Press, 1990.
71. Hagmar L, Bellander T, Persson L, et al. Biological effects in a chemical factory with mutagenic exposure. III. Urinary mutagenicity and thioether excretion. Int Arch Occup Environ Health 1988; 60:453-456.
72. Falck K, Grohn P, Sorsa M, Vaino H, Heinoren E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1(8128):1250-1251.
73. Harrison BR. Risks of handling cytotoxic drugs. In: Perry MC, ed. The Chemotherapy Source Book. 3rd ed. Williams and Wilkins: Philadelphia, Lippincott, 2001.
74. National Institute of Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other drugs in health care settings. Washington: U.S. Department of Health and Human Services, 2004.
75. Skov TB, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992; 49:855-861.
76. McDiarmid MA, Egan MA, Furio T, Bonacci M, Watts SR. Sampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm 1986; 43:1942-1945.
77. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Hosp Pharm 1999; 56:1427-1432.
78. Larson RR, Khazaeli MB, Dillon HK. A new monitoring method using solid sorbant media for evaluation of airborne cyclophosphamide and other antineo-plastic agents. Appl Occup Environ Hygiene 2003; 18:120-131.
79. Anderson RW, Puckett WH, Dana WJ, Nguyen TV, Theiss JC, Matney TS. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39:1881-1887.
80. Sessink PJM, Wittenhorst BJ, Anzion RBM, Bos RP. Exposure of pharmacy technicians to antineoplastic agents. Arch Environ Health 1997; 52:240-244.
81. Sargent EV, Kirk GD. Establishing airborne exposure control limits in the pharmaceutical industry. Am Ind Hygiene Assoc J 1988; 49:309-313.
82. Sargent EV, Naumann BD. Occupational exposure limits. In: Alaimo RJ, ed. Handbook of Chemical Health and Safety. Washington: Oxford University Press, 2001:75-80.
83. Garte S. Metabolic susceptibility genes as cancer risk factors. Cancer Epidemiol Biomarkers Prev 2001; 10:1233-1237.